ArticleBiology methods & protocols2025
Optimization of the HS-GC/MS technique for urine metabolomic profiling.
Article in Biology methods & protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Headspace gas chromatography-mass spectrometry (HS GC-MS) traditionally has been applied to analyze samples with a high content of volatile components, such as stool samples. Nevertheless, other types of samples-for example, urine-may also contain volatile compounds and serve as valuable sources of diagnostic information. However, the content of volatile components in urine is considerably lower than in stool samples, necessitating modification of the HS GC/MS method. Such optimization could be particularly valuable for patients with inflammatory bowel disease (IBD), for whom providing a stool sample can sometimes be challenging. The aim of this work was to optimize a method for assessing volatile components in urine samples. Methods: Urine samples were collected from 10 patients with IBD and 10 healthy controls. Laboratory, endoscopic, and histopathological analyses confirmed the IBD diagnosis. Metabolomic profiling was performed using HS GC/MS (Shimadzu QP2010 Ultra with HS-20 extractor). Results: Volatile metabolites in urine samples suitable for analysis were acquired through optimized sample preparation procedures, including sampling vapor with a salt mixture, increasing the sample volume, adjusting the temperature regime during preparation, and fine-tuning the delay time prior to mass spectrometer activation. The most comprehensive and high-quality results were obtained using a triple extraction method with cryo-trap technology. As a result of HS GC/MS method optimization, urine metabolome analysis of IBD patients enabled the identification of biomarkers that can be utilized for the clinical detection of IBD. 2-Heptanone and pentadecane were identified as IBD-associated biomarkers. Conclusions: Optimized preparation protocols enable HS GC/MS method to be effectively applied for the analysis of volatile components in urine samples. The modified HS GC/MS method can be scaled up for large-sample analysis to both detect identified metabolites and explore potential new biomarkers associated with IBD and other pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.